Diem, Stefan

Management of toxicities of immune checkpoint inhibitors

Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 854

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

Berner, F., Bomze, D., Diem, S., Ali, O. H., Fässler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersChemotherapy-related skin toxicity

Cited by 395

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., & Larkin, J. (2016) · British Journal of Cancer

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 308

Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma

Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 190

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors

Hasan Ali, O., Berner, F., Bomze, D., Fässler, M., Diem, S., Cozzio, A., Jörger, M., Früh, M., Driessen, C., Lenz, T. L., et al. (2019) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 187